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Excessive inflammation by phagocytes during Aspergillus fumigatus infection is thought
to promote lung function decline in CF patients. CFTR modulators have been shown to
reduce A. fumigatus colonization in vivo, however, their antifungal and anti-inflammatory
mechanisms are unclear. Other treatments including azithromycin and acebilustat may
dampen Aspergillus-induced inflammation due to their immunomodulatory properties.
Therefore, we set out in this study to determine the effects of current CF therapies on ROS
production and fungal killing, either direct or indirect by enhancing antifungal immune
mechanisms in peripheral blood immune cells from CF patients upon A. fumigatus
infection. Isolated peripheral blood mononuclear cells (PBMCs) and polymorphonuclear
cells (PMNs) from CF patients and healthy volunteers were challenged with A.
fumigatus following pre-treatment with CFTR modulators, azithromycin or acebilustat.
Ivacaftor/lumacaftor treated CF and control subject PMNs resulted in a significant
reduction (p < 0.05) in Aspergillus-induced ROS. For CF PBMC, Aspergillus-induced
ROS was significantly reduced when pre-treated with ivacaftor alone (p < 0.01) or in
combination with lumacaftor (p< 0.01), with a comparable significant reduction in control
subject PBMC (p< 0.05). Azithromycin and acebilustat had no effect on ROS production
by CF or control subject phagocytes. None of the treatments showed an indirect or
direct antifungal activity. In summary, CFTR modulators have potential for additional
immunomodulatory benefits to prevent or treat Aspergillus-induced inflammation in CF.
The comparable effects of CFTR modulators observed in phagocytes from control
subjects questions their exact mechanism of action.
Keywords: Aspergillus fumigatus, cystic fibrosis, phagocytes, inflammation, CFTR modulators, azithromycin,
acebilustat
INTRODUCTION
Cystic fibrosis (CF) is a life-limiting autosomal recessive disorder characterized by chronic
respiratory infections, progressive respiratory disease and respiratory failure (Elborn, 2016). Gene
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) in epithelial cells
affects mucus fluid dynamics and pathogen survival (Elborn, 2016; McElvaney et al., 2019).
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CFTR is also expressed in immune cells and mutations in
this gene are associated with impaired antimicrobial activity
and dysregulated inflammatory responses (Moss et al., 2000;
Carrabino et al., 2006; Painter et al., 2006; Deriy et al., 2009;
Del Porto et al., 2011; Mueller et al., 2011; Zhou et al., 2013;
Johansson et al., 2014). Treatment of the bacterial infectious
complications in CF patients has traditionally focused on
clearance and eradication of the pathogen from the airways,
thereby diminishing and preventing airway inflammation
(Döring et al., 2012; Ciofu et al., 2013; Addy et al., 2020).
Airway inflammation in CF is a much-debated topic, as
underlying mechanisms may be either intrinsic or extrinsic, or
a combination of both (Nichols and Chmiel, 2015). Modulating
the inflammatory response needs to consider a careful balance
aimed at a minimum of inflammation without reducing the
antimicrobial activity of the immune system. Management
approaches to Aspergillus infections in CF have focused on
Allergic Bronchopulmonary Aspergillosis (ABPA) by reducing
the allergic inflammation induced (Agarwal et al., 2016). First-
line treatment with corticosteroids is targeted against the induced
inflammation, with a recommendation for antifungal therapy
when first-line treatment fails. Aspergillus fumigatus is the major
fungal pathogen isolated from sputum of far more CF patients
than those diagnosed with ABPA (Warris et al., 2019). Studies
indicate that infection with A. fumigatus in the CF airways can
result in increased pulmonary exacerbations, bronchiectasis, and
worse respiratory quality of life (Amin et al., 2010; Breuer et al.,
2019; Hong et al., 2020). Nevertheless, there is a lack of data on
how to manage those infections, e.g., eradication of infection or
damping the inflammation, and what the associated risks and
benefits of such approaches would be.
Our group previously demonstrated that peripheral blood
phagocytes from CF patients show normal antifungal killing in
response to A. fumigatus, but that this is associated with excessive
reactive oxygen species (ROS) production (Brunel et al., 2018).
Additionally, we highlighted that the heightened inflammation
was correlated with poorer lung function in CF patients. As
eradication of A. fumigatus from the airways of CF patients is
a huge challenge due to the universal presence of A. fumigatus
in the environment, finding ways to dampen Aspergillus-induced
inflammation may be more feasible, as long as these strategies do
not affect antifungal killing mechanisms.
In our current study, a key objective was to determine in
detail the effects of three important CF therapies, azithromycin,
acebilustat, and CFTR modulators, on the antifungal immune
mechanisms. Azithromycin is a macrolide antibiotic with
immunomodulatory and anti-inflammatory properties (Cigana
et al., 2006; Legssyer et al., 2006) used as a long-term
treatment for CF patients to improve lung function and reduce
exacerbations in those with persistent Pseudomonas aeruginosa
(Mogayzel et al., 2013; Principi et al., 2015). Acebilustat,
currently in phase I/II trials in CF patients, is a leukotriene
A4 hydrolase (LTA4H) inhibitor, inhibiting the production of
the intracellular lipid mediator leukotriene B4 (LTB4) (Bhatt
et al., 2017; Elborn et al., 2017a,b, 2018). LTB4 is a principal
chemoattractant for recruiting neutrophils to inflamed sites
across the airway epithelium and known to stimulate ROS
production and to enhance the NF-κB pathway, thus driving
inflammation (Woo et al., 2003). CFTR modulators are the first
causative treatment option for CF and have been shown to
reduce pulmonary exacerbations in CF patients homozygous for
the F508-del mutation (Wainwright et al., 2015). Additionally,
ivacaftor reduced colonization and prevalence of A. fumigatus
in CF patients with a G551D genotype (Heltshe et al., 2015;
Frost et al., 2019). Whilst the effects of CFTR modulators on
epithelial cell function are reasonably well-understood (Kuk and
Taylor-Cousar, 2015), the effects on immune cell function have
not been investigated in detail. Assessment of the hypothetical
effect of the CFTR modulators on immune cells resulting in a
decrease of microbial induced inflammation, is of high value.
We present here our results of the effect of these treatments on
Aspergillus-induced ROS production and fungal killing, either
direct or indirect by enhancing antifungal immune mechanisms
in peripheral blood phagocytes.
MATERIALS AND METHODS
Human Subjects
Blood samples were donated by adult CF patients attending
the Aberdeen Royal Infirmary (Aberdeen, UK) and healthy
volunteers recruited from the Institute of Medical Sciences
(Aberdeen, UK). All participants provided written informed
consent and donated a maximum of 50mL (CF patients) or
100mL (healthy volunteers) of blood. This study was approved
by East of Scotland Research Ethics Service (18/ES/0154) and
the College Ethics Review Board of the University of Aberdeen
(CERB/2016/8/1300). All samples were collected according to
approved guidelines and procedures. Clinical report forms were
provided for each CF patient and included; demographics,
genotype, body mass index (BMI), forced expiratory volume
in 1 s (FEV1), Aspergillus serology, sputum culture results, co-
morbidities, pulmonary exacerbation episodes over the previous
12 months and medications.
A. fumigatus Strains
Thirteen A. fumigatus strains were used including 12 clinical
strains and the well-characterized laboratory strain AF 293.
Clinical isolates from CF patients (10,749, 11,361, 5,923, 7,762,
10,225, 15,115, 10,410, 11,856), patients with chronic infection
(1,145, 9,475) and acute infection (11,146, 11,160) were kindly
provided by Prof Paul E. Verweij (Centre for Expertise in
Mycology, Radboud University Medical Centre, Nijmegen, NL).
A. fumigatus Culture Conditions
A. fumigatus conidia were grown on glucose minimal media for
7 days at 35◦C and harvested in phosphate buffer saline (PBS)
supplemented with 0.05% Tween-80. Conidia were then filtered
through a 40µm sterile filter and resuspended to the required
concentration in RPMI or PBS + Ca2+/Mg2+ (0.9 nM Ca2+ and
0.49 mMMg2+).
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CFTR Modulators, Azithromycin, and
Acebilustat
Ivacaftor and lumacaftor (AdooQ Bioscience, USA) stock
solutions were prepared by solubilizing in 100% DMSO (Sigma
Aldrich, UK) at 10 mg/mL. CFTRmodulator stock solutions (1.6,
3.2, or 6.4 µl) were diluted in 1mL sterile water. DMSO diluted
in sterile water was used as a control in all experiments, at 0.32
or 0.64% when testing direct antifungal activity and 0.16% for
ROS assays. Azithromycin dihydrate (Sigma Aldrich, UK) was
solubilised in 100% DMSO at 20 mg/mL and stock solutions (1,
2, and 2.5 µl) were diluted in 1mL of sterile water for ROS assays
and RPMI for fungal killing. Acebilustat (MedChemExpress,
USA) was solubilised in 100% DMSO at 0.1mM and diluted to
a working concentration of 10µM in sterile water for ROS assays
and RPMI for fungal killing.
Concentrations used in the various experiments were based
the IC50 of acebilustat to inhibit LTB4 production, the maximum
reported tissue concentrations of azithromycin, and previous in
vitro studies performed with the CFTR modulators (reviewed by
Csanády and Töröcsik, 2019).
Phagocyte Isolation
Whole blood samples were collected in a Vacuette R© containing
EDTA (Greiner Bio-One) and allowed to cool to room
temperature before mixing 1:1 with sterile PBS. Blood was
then overlaid on equal parts of Histopaque (10,771 and 11,919;
Sigma Aldrich) and separation of the cell fractions was achieved
by density gradient centrifugation at 300 g for 30min at
4◦C. The peripheral blood mononuclear cell (PBMC) layer
was removed and washed three times in PBS. The fraction
containing polymorphonuclear cells (PMN) was treated twice
with hypotonic lysis buffer (8.3 mg/ml NH4Cl and 1 mg/ml
KHCO3 in sterile water) to lyse erythrocytes then washed three
times with decreased spins to remove thrombocytes. PBMC and
PMN pellets were resuspended in RPMI or PBS + Ca2+/Mg2+,
counted and adjusted to the required concentration. Viability was
tested by using trypan blue exclusion.
Reactive Oxygen Species (ROS) Production
Production of oxygen radicals was evaluated using luminol-based
chemiluminescence as previously described (Brunel et al., 2018).
Briefly, PBMCs and PMNs were suspended in PBS+Ca2+/Mg2+
and plated at 5 × 105 cells/well and left untreated (vehicle
control) or pre-treated with ivacaftor (8µg/ml), lumacaftor
(8µg/ml), ivacaftor+lumacaftor (8µg/ml of each), acebilustat
(0.031µg/ml) or azithromycin (20µg/ml) for 1 h at 37◦C, 5%
CO2. Cells were then infected withA. fumigatus resting conidia (1
× 107/well) and 100µM luminol was added to each well. Kinetic
reads were taken every 180 s for 2 h using a luminescence plate
reader (Biotek Gen5TM).
Fungal Killing
To assess direct fungal killing of each drug, A. fumigatus strains
were plated at 5 × 104 conidia per well in RPMI in a 96 U-well
plate. Conidia were then incubated with ivacaftor/lumacaftor
(16 or 32µg/ml of each), azithromycin (10, 20, or 50µg/mL),
or acebilustat (0.031µg/ml) for 18 h or left untreated (vehicle
control). To test anti-hyphal activity; conidia were plated and
left for 16 h (37◦C, 5% CO2) to allow for gemination prior to
incubation with ivacaftor (16 or 32µg/ml), lumacaftor (16 or
32µg/ml), or ivacaftor+lumacaftor (16 or 32µg/ml of each)
for 6 h.
To assess enhanced fungal killing by phagocytes, PMNs
and PBMCs were plated at 1 × 105 and 5 × 105 cells
per well respectively, and left untreated (vehicle control) or
pre-treated with ivacaftor (8µg/ml), lumacaftor (8µg/ml),
ivacaftor/lumacaftor (8µg/ml of each), acebilustat (0.031µg/ml)
or azithromycin (20µg/ml) for 1 h at 37◦C, 5% CO2. Cells were
then infected withA. fumigatus conidia (1× 105 conidia per well)
and left for 18 h at 37◦C, 5% CO2.
Following the indicated incubation times, plates were
centrifuged at 2,500 g for 10min. For phagocyte experiments,
media was removed, and cells lysed with 100 µl of saponin
(0.005% in MilliQ water; Sigma Aldrich) for 20min. For the cell-
free experiments, fresh media was added. Twice concentrated
XTT-menadione solution (XTT salt 200µg/ml, Invitrogen;
menadione crystalline 172µg/ml, Sigma Aldrich) was added to
each well (100 µl diluted 1:2 in media or saponin) and plates left
for 2–3 h in the dark at 37◦C, 5% CO2 to allow for reduction
of XTT to formazan. Plates were spun at 2,500 g for 10min
and supernatant transferred to a flat-bottomed 96-well plate
prior to measuring absorbance at 450 nm using a VersaMax
microplate reader.
Statistical Analysis
All data are presented as mean ±SEM. Significance between
control subjects and CF patients was analyzed using Mann
Whitney U-tests. For multiple comparisons between drug
treatments a Kruskal–Wallis test was used with Dunn’s post-test.
Data analysis was carried out using GraphPad Prism V5.04.
RESULTS
Clinical Characteristics of Participants
Ten patients (60% male) participated in this study with a median
age of 26 years (range 16–46 years). Six were homozygous
for the F508-del mutation. Median FEV1 was 43.5% predicted
(range 15–104.2%) and BMI was 21 (range 17–40). None of
the patients received CFTR modulators or antifungals. Four
patients had signs of fungal sensitization (Aspergillus IgE > 1
kU/L) (Supplementary Table 1). Control subjects were between
the ages of 20–55 years.
CFTR Modulators and Azithromycin Have
no Direct Antifungal Effect
Ivacaftor (16 or 32µg/ml), lumacaftor (16 or 32µg/ml),
or ivacaftor/lumacaftor (16 or 32µg/ml of both) did not
have a significant effect on the hyphal metabolic activity for
both A. fumigatus isolates when compared to the vehicle
controls (Figure 1A). No direct effect was observed on the
metabolic activity of an additional 10 clinical isolates and one
lab strain (AF293) with all concentrations and combination
tested (Supplementary Figure 1). When incubatingA. fumigatus
conidia with ivacaftor/lumacaftor (16 or 32µg/ml of both),
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FIGURE 1 | CFTR modulators and azithromycin have no direct antifungal effect. (A) Hyphae from 2 clinical A. fumigatus isolates (11,361, 15,115) were untreated
(DMSO) or treated with ivacaftor (16 or 32µg/ml), lumacaftor (16 or 32µg/ml) or ivacaftor/lumacaftor (16 or 32µg/ml of each) for 6 h prior to measuring metabolic
activity. (B) Two clinical A. fumigatus isolates (11,361, 15,115) were grown in the presence of DMSO or ivacaftor/lumacaftor (16 or 32µg/ml of each) or (C) in the
presence of various concentrations of azithromycin for 18 h at 37◦C, 5% CO2. Following the specified incubations metabolic activity was assessed with
XTT-menadione. Data are representative of 2 (A,B) and 3 (C) independent experiments and are presented the mean ±SEM of % metabolic activity compared to A.
fumigatus grown in RPMI only.
no effect on the metabolic activity was observed when
compared to the vehicle controls (Figure 1B). Again, no effect
was observed for an additional 10 clinical isolates and one
lab strain (AF293) (Supplementary Figure 2). No effect on
fungal metabolic activity was observed for all azithromycin
concentrations tested (Figure 1C, Supplementary Figure 3).
Aspergillus Activated Phagocytes From CF
Patients Show Exaggerated ROS
Production
Phagocytes from CF and control subjects were co-incubated with
A. fumigatus conidia and analyzed for ROS production. ROS
production after incubation with two different clinical isolates
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FIGURE 2 | CFTR modulators, but not acebilustat or azithromycin, reduce Aspergillus-induced ROS production by both healthy and CF phagocytes. Isolated PMN or
PBMC were either untreated (0.16% DMSO) or treated with ivacaftor (8µg/ml), lumacaftor (8µg/ml), ivacaftor/lumacaftor (8µg/ml of both), acebilustat (0.031µg/ml)
or azithromycin (20µg/ml) for 1 h at 37◦C, 5% CO2 prior to A. fumigatus infection (MOI 20). ROS was measured by luminol chemiluminescence. (A) ROS production
by control and CF PMN and PBMC in response to A. fumigatus CF patient isolates 11,361 and 15,115. (B–D) ROS production by control and CF PMN in response to
two A. fumigatus isolates originating from CF patients following pre-treatment with ivacaftor, lumacaftor, acebilustat or azithromycin and (C–E) and by control and CF
(Continued)
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FIGURE 2 | PBMC. Data presented relative to untreated samples which was set as 100%. Data are presented as mean ±SEM of total ROS produced over 2 h (AUC)
for 4–5 control subjects and 5–9 CF patients. Statistical analysis was carried out using (A) Mann-Whitney test and (B–E) Kruskal-Wallis test. Abbreviations, AUC; area
under the curve, PMN; polymorphonuclear cells, PBMC; peripheral blood mononuclear cells, ROS; reactive oxygen species, SEM; standard error of the mean. *p ≤
0.05; **p ≤ 0.001; ***p ≤ 0.001.
of A. fumigatus conidia was significantly increased by CF PMN
and PBMC when compared to healthy controls (Figure 2A)
confirming our previous observations (Brunel et al., 2018). CF
PMN produced ROS at levels up to 4-fold greater than PMNs
from control subjects in response to both A. fumigatus isolates
(p ≤ 0.01). A. fumigatus-induced ROS production by CF PBMC
was 18- to 20-fold higher (p≤ 0.01) when compared to cells from
control subjects (Figure 2A).
CFTR Modulators Reduce
Aspergillus-Induced ROS by Phagocytes
The viability of the phagocytes with or without the CFTR
modulators (alone or in combination at 8µg/mL) remained
around 95% after 6 h incubation. To assess the effect of each
treatment on Aspergillus-induced ROS production by healthy
and CF phagocytes, we normalized each treatment response
as a percentage of the untreated control. A decrease in ROS
production by CF PMN was observed following pre-treatment
with ivacaftor (11,361; −33.4 ± 25.9%, 15,115; −24.1 ± 27.5%)
and lumacaftor (11,361;−48.9± 11.01%, 15,115;−45.3± 9.5%)
when compared to untreated controls, although the changes
did not reach statistical significance. Ivacaftor/lumacaftor pre-
treatment resulted in a significant reduction of Aspergillus-
induced ROS production by CF PMNs for both strains
(11,361; −67.8 ± 10.8%, 15,115; −62.8 ± 11.6%, p ≤ 0.05)
(Figures 2B,D).
The same trend was observed in PMN from control subjects;
ivacaftor (11,361; −52.5 ± 23.0%, 15,115; −45.3 ± 26.3%) and
lumacaftor (11,361; −39.33 ± 8.7%, 15,115; −45.4 ± 6.0%)
reduced ROS levels, although not statistically different from
untreated PMN. When PMN from control subjects were pre-
treated with ivacaftor/lumacaftor, this significantly reduced ROS
production in response to both strains (11,361; −66.8 ± 9.7%,
15,115;−75.8± 7.1%, p ≤ 0.05) (Figures 2B,D).
For CF PBMC, Aspergillus-induced ROS was significantly
reduced when pre-treated with ivacaftor (11,361; −81.7 ±
14.6%, p ≤ 0.05; 15,115; −76.60 ± 11.89%, p ≤ 0.01), but not
when treated with lumacaftor (11,361; −41.9 ± 6.3%; 15,115;
−38.2 ± 5.8%). Ivacaftor/lumacaftor pre-treatment significantly
attenuated generation of ROS by CF PBMCs (11,361; −87.96 ±
9.7%, p≤ 0.01; 15,115;−85.9± 6.7%, p≤ 0.001) (Figures 2C,E).
As observed with CF PBMC, pre-treatment of control PBMC
with ivacaftor showed a clear decrease in ROS production
(11,361; −79.7 ± 14.6%, p ≤ 0.05; 15,115 −71.32 ± 22.4%, p =
n.s.). Ivacaftor/lumacaftor significantly reduced ROS production
by control subject PBMC (11,361;−92.5± 11.7%, 15,115;−89.14
± 7.57%, p ≤ 0.05 for both strains) (Figures 2C,E).
Next, we assessed the differential effects of those treatments
based on underlying CFTR genotypes. PMN and PBMC from
CF patients homozygous for the F508-del mutation (n = 6)
treated with ivacaftor/lumacaftor showed a significant reduction
in ROS (–54.2 ± 11.0%; p ≤ 0.01) and (−86.6 ± 5.7%; p
≤ 0.001, respectively) (Figure 3). Ivacaftor alone significantly
reduced ROS production by PBMC homozygous for the F508-
del mutation (−80.0 ± 8.1%; p ≤ 0.05), but had no effect on
PMN (F508-del/F508-del). Lumacaftor pretreatment of PMN
and PBMC resulted in a 33.0% (±11.1%) and 41.35% (±5.3%)
reduction, respectively, in the F508-del homozygous group which
was not significantly different to untreated cells (Figure 3).
Treatment with ivacaftor alone or in combination with
lumacaftor showed a significant decrease in Aspergillus-induced
ROS production by PMN (−93.8 ± 4.5 and −85.9 ± 5.6%,
respectively) and PBMC (−96.4 ± 2.2 and −94.7 ± 3.2%,
respectively) from CF patients with other CFTR mutations (non
F508-del, non G551D) (Figure 3).
Pre-treatment with azithromycin (20µg/ml) or acebilustat
(64 nM) had no effect on Aspergillus-induced ROS production by
PMN or PBMC from either CF patients or control subjects when
compared to untreated cells (Figures 2B–E).
CFTR Modulators, Acebilustat, and
Azithromycin Do Not Impair Fungal Killing
by Healthy and CF Phagocytes
Control subject PMN reduced metabolic activity by ∼70%
for both A. fumigatus isolates (Figures 4A,C). In comparison,
CF PMN reduced the metabolic activity of the two isolates
between 80 and 92% (Figures 4A,C). None of the treatments
had any effect on killing of the two A. fumigatus isolates by
both CF and control subject PMN when compared to untreated
controls (Figures 4A,C). CF PBMC showed an increased killing
of both isolates but changes did not reach statistical significance
when compared to control subject PBMC (Figures 4B,D).
No significant differences in antifungal killing were observed
associated with a specific treatment given compared to untreated
CF and control subject PBMC (Figure 4B).
DISCUSSION
We show that the CFTR modulators, ivacaftor, lumacaftor and
its combination, are able to downregulate ROS production
by human CF phagocytes without compromising their fungal
killing ability. Importantly, this effect was not specific to CF
cells, indicating potential off-target mechanistic effects of CFTR
modulators. To our knowledge we are the first to demonstrate
that CFTR modulators have immunomodulatory effects on
both CF and control subjects’ phagocytes when challenged
with A. fumigatus. Azithromycin and acebilustat did not affect
ROS production or fungal killing by CF or control subjects’
phagocytes. Furthermore, CFTR modulators and azithromycin
do not directly affect fungal viability.
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FIGURE 3 | CFTR modulators differentially influence ROS production based on CFTR genotypes and type of immune cells. Isolated PMN or PBMC from CF patients
with different underlying CFTR gene mutations were either untreated (0.16% DMSO) or treated with ivacaftor (8µg/ml), lumacaftor (8µg/ml), ivacaftor/lumacaftor
(8µg/ml of both) for 1 h at 37◦C, 5% CO2 prior to A. fumigatus infection (MOI 20). ROS was measured by luminol chemiluminescence. (A) ROS production by CF
PMN in response to two clinical A. fumigatus isolates from CF patients (11,361 and 15,115) following pre-treatment with ivacaftor, lumacaftor, and (B) by CF PBMC.
Data presented relative to untreated samples which was set as 100%. Data are presented as mean ±SEM of total ROS produced over 2 h (AUC) for 5–9 CF patients.
AUC, area under the curve; PMN, polymorphonuclear cells; PBMC, peripheral blood mononuclear cells; ROS, reactive oxygen species; SEM, standard error of the
mean. *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.001.
Our study shows that CFTR modulators reduce ROS
responses by human CF phagocytes infected with A. fumigatus,
and that this reduction was statistically significant in PMN and
PBMC from patients homozygous for the F508-del mutation
treated with ivacaftor/lumacaftor. In addition, pretreatment of
PBMC homozygous for the F508-del mutation with ivacaftor
alone significantly reduced the Aspergillus-induced ROS
production. As the number of CF patients heterozygous for the
F508-del mutation and those with other mutations (non F508-
del, non G551D) were low (both n = 2), a proper comparison
between the three groups was not possible. Nevertheless, a
comparable trend was observed for the phagocytes from CF
patients heterozygous for the F508-del mutation. Remarkable is
the observation that in the two CF patients with non-F508-del
and non-G551D mutations, treatment with ivacaftor alone and
in combination with lumacaftor almost completely abolished the
Aspergillus-induced ROS production in PMN and PBMC. Most
of the observed differences can be related to the specific mode
of action of ivacaftor and lumacaftor. Lumacaftor acts directly
to improve the defective cellular processing and trafficking of
the F508-del mutant CFTR channel, with ivacaftor potentiating
the gating properties of the mutant CFTR channel caused by a
variety of gene mutations (Kuk and Taylor-Cousar, 2015).
The differential effect of ivacaftor pretreatment leading to
a significant reduction in Aspergillus-induced ROS production
by CF PBMC is in sharp contrast with the effect observed on
CF PMN. A higher sensitivity of CF PBMC for potentiating
the channel function might explain this observation, but needs
further research. Improvements of ion fluxes underpinning the
clinical efficacy of the CFTR modulators will likely influence the
aberrant immune responses and observed hyperinflammation
(Hartl et al., 2012; Pohl et al., 2014).
Only limited data is available showing that
ivacaftor/lumacaftor can directly modulate CF-related
inflammation. Studies performed with P. aeruginosa stimulated
CF bronchial epithelial cells (homozygous for F508-del) showed
that this combination reduces the transcription of CXCL8
and the phosphorylation of p38 MAPK (Ruffin et al., 2018).
Human CF monocytes (homozygous for F508-del) stimulated
with LPS/ATP before and after patients received treatment
with ivacaftor/lumacaftor showed decreased levels of IL-18,
TNF and caspase-1 (Jarosz-Griffiths et al., 2020). Excessive
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FIGURE 4 | CFTR modulators, acebilustat and azithromycin do not impair fungal killing by healthy and CF phagocytes. Isolated PMN or PBMC were either untreated
(0.16% DMSO) or treated with ivacaftor (8µg/ml), lumacaftor (8µg/ml), ivacaftor/lumcaftor (8µg/ml of both), acebilustat (0.031µg/ml) or azithromycin (20µg/ml) for
1 h at 37◦C, 5% CO2 prior to A. fumigatus infection (PMNs MOI: 1; PBMCs MOI: 0.2). Following 18 h incubation metabolic activity was determined using
XTT-menadione. Assessment of fungal metabolic activity following co-incubation with pre-treated control and CF PMN (A,C) and PBMC (B,D) compared to untreated
cells. Data are presented as mean ±SEM for 4–5 healthy controls and 3–6 CF patients. Statistical analysis was carried out using Kruskal–Wallis test. PMN,
polymorphonuclear cells; PBMC, peripheral blood mononuclear cells; SEM, standard error of the mean.
ROS production is linked to defective autophagy (Luciani
et al., 2011). In CF epithelial cells, stockpiling of large amounts
of mutant CFTR leads to increases in aggresomes and ROS
production, and autophagy inhibition (Luciani et al., 2010). A
comparable phenomenon has been observed in CF macrophages
(Abdulrahman et al., 2013). CFTR modulators have been shown
to have the ability to target autophagy in CF airway epithelial
cells to decrease inflammation in the lung (Luciani et al., 2012)
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and might underpin the reduced ROS production as shown in
our results.
Remarkably, ivacaftor and lumacaftor also decreased
Aspergillus-stimulated ROS production by phagocytes from
control subjects. Potentiation of the CFTR channel above normal
physiological function or yet unknown off-target effects might
explain this observation. It is important to acknowledge that the
exact mechanisms of action have not been elucidated for both
ivacaftor and lumacaftor.
Azithromycin did not affect the ROS production by CF
or control subjects’ phagocytes in response to A. fumigatus.
Azithromycin has both immunomodulatory and anti-
inflammatory properties (Cigana et al., 2006; Legssyer et al.,
2006) and accumulates in neutrophils (Bosnar et al., 2005), but
the effect on ROS production has hardly been studied. Bystrzycka
et al. (2017) demonstrated a concentration-dependent effect of
azithromycin (0.5–50µg/ml) in decreasing the amount of ROS
produced by PMA stimulated healthy human neutrophils. Earlier
studies suggest that the effect of azithromycin depends on the
stimulus used (Culić et al., 2002; Parnham et al., 2005). Due to
the systemic glutathione deficiency in CF patients, azithromycin
may be of value to improve the antioxidant activities by CF
cells, thereby diminishing the toxic effects of ROS on lung tissue
(Roum et al., 1993).
Acebilustat has not been investigated with respect to its
influence on ROS production in immune cells. Based on the
fact that LTB4 induces ROS production by dHL-60 neutrophils,
inhibition of LTA4H by acebilustat would be predicted to
diminish ROS production (Woo et al., 2003). However,
acebilustat had no effect on ROS production by either CF or
control subjects’ phagocytes in our study. Its anti-inflammatory
properties in the inflamed lung are most likely attributed to its
inhibitory effects on neutrophil migration into the airways and
the lungs (Woo et al., 2003).
Pretreatment with CFTR modulators was not associated
with an enhanced fungal killing by CF and control subjects’
phagocytes. This is in contrast with reports that CFTR
modulators augment bacterial killing. Ivacaftor has been shown
to augment killing of P. aeruginosa by CF macrophages
(G551D/F508-del) to the same degree as healthy cells (Pohl
et al., 2014). Similarly, lumacaftor alone increased killing of P.
aeruginosa by CFmacrophages (homozygous for Phe508del), but
no effect was seen on control subjects’ monocytes (Barnaby et al.,
2018).
Azithromycin pre-treatment of healthy and CF phagocytes
did not influence fungal killing. A different observation is
reported for bacterial killing, as azithromycin-loaded neutrophils
showed more effective killing of Aggregatibacter sp. by increased
phagocytosis (Lai et al., 2015). Despite reports demonstrating
that macrolide antibiotics have in vitro antifungal activity against
Aspergillus species and other fungi (Kim et al., 2003; Hosoe
et al., 2006), we did not observe any direct antifungal effect
of azithromycin. Previous studies show long term azithromycin
treatment can result in increased risk of colonization with A.
fumigatus in CF patients possibly associated with its inhibitory
effect on immune responses (Legssyer et al., 2006; Jubin et al.,
2010). Additionally, there is an association between A. fumigatus
colonization and non-tuberculous mycobacteria (NTM) in CF
patients (Coolen et al., 2015). Although long term azithromycin
reduces the risk of NTM, it does not suggest additional benefits
to prevent Aspergillus infections.
Ivacaftor has been shown to have direct antibacterial effects
against Staphylococcus aureus (MIC 8µg/ml) and Streptococcus
spp. (MIC 32µg/ml), but was not active against P. aeruginosa
(Reznikov et al., 2014). Similarly, Payne et al. (2017) showed
32 mg/L of ivacaftor resulted in a several log-fold decrease in
CFUs with Streptococcus spp. and bacteriostatic effects against
S. aureus, but was ineffective against P. aeruginosa. Clinical
studies have shown ivacaftor reduces colonization ofA. fumigatus
in CF patients (with at least one copy of G551D mutation)
and P. aeruginosa, but not S. aureus (Heltshe et al., 2015).
Using data from the UK CF Registry comparing ivacaftor users
and their contemporaneous comparators, reduced prevalence
of Aspergillus spp., as well as P. aeruginosa and S. aureus, but
not Burkholderia cepacia were found (Frost et al., 2019). We
show that ivacaftor and/or lumacaftor have no antifungal activity,
suggesting that reduced colonization observed clinically is not
due to a direct effect. Synergy in bacterial killing by combining
CFTR modulators and specific antimicrobials indicates possible
additional benefit to treat CF lung infections. Schneider et al.
(2016) found that using ivacaftor or ivacaftor/lumacaftor in
combination with polymyxin B increases killing of P. aeruginosa.
Ivacaftor in combination with vancomycin or ciprofloxacin
increased the potency of these antibiotics against S. aureus and
P. aeruginosa, respectively (Reznikov et al., 2014). Comparable
studies with antifungal drugs are lacking. However, for the most
commonly used antifungals, the mold-active azoles, an extra
challenge is faced when co-prescribing these two drugs due to
drug-drug interactions (Jordan et al., 2016).
In summary, CFTR modulators may have additional
immunomodulatory benefits to prevent or treat Aspergillus-
induced inflammation in CF. The comparable effects of CFTR
modulators observed in phagocytes from control subjects
questions their exact mechanism of action.
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